title: Hydrogen bonding between the 17beta-substituent of a neurosteroid and the GABA(A) receptor is not obligatory for channel potentiation.
abstract: OBJECTIVE
  Potentiating neurosteroids are some of the most efficacious modulators of the mammalian GABA(A) receptor. One of the crucial interactions may be between the C20 ketone group (D-ring substituent at C17) of the neurosteroid, and the N407 and Y410 residues in the M4 domain of the receptor. In this study, we examined the contribution of hydrogen bonding between 17beta-substituents on the steroid D-ring and the GABA(A) receptor to potentiation by neurosteroids.
  
  
  METHODS
  Whole-cell and single-channel recordings were made from HEK 293 cells transiently expressing wild-type and mutant alpha1beta2gamma2L GABA(A) receptors.
  
  
  RESULTS
  A steroid with a 17beta-carbonitrile group (3alpha5alpha18nor17betaCN) was a potent and efficacious potentiator of the GABA(A) receptor. Potentiation was also shown by a cyclosteroid in which C21 and the C18 methyl group of (3alpha,5alpha)-3-hydroxypregnan-20-one are connected within a six-membered ring containing a double bond as a hydrogen bond acceptor (3alpha5alphaCDNC12), a steroid containing a 17beta-ethyl group on the D-ring (3alpha5alpha17betaEt) and a steroid lacking a 17beta-substituent on the D-ring (3alpha5alpha17H). Single-channel kinetic analysis indicates that the kinetic mechanism of action is the same for the neurosteroid 3alpha5alphaP, 3alpha5alpha18nor17betaCN, 3alpha5alphaCDNC12, 3alpha5alpha17betaEt and 3alpha5alpha17H. Interestingly, 3alpha5alpha17betaEt, at up to 3 microM, was incapable of potentiating the alpha1N407A/Y410F double mutant receptor.
  
  
  CONCLUSIONS
  Hydrogen bonding between the steroid 17beta-substituent and the GABA(A) receptor is not a critical requirement for channel potentiation. The alpha1N407/Y410 residues are important for neurosteroid potentiation for reasons other than hydrogen bonding between steroid and receptor.
authors.affiliation: Department of Anesthesiology, Washington University in St Louis, St Louis, MO 63110, USA.
authors.forename: Ping
authors.initials: P
authors.lastname: Li
authors.forename: Achintya K
authors.initials: AK
authors.lastname: Bandyopadhyaya
authors.forename: Douglas F
authors.initials: DF
authors.lastname: Covey
authors.forename: Joe Henry
authors.initials: JH
authors.lastname: Steinbach
authors.forename: Gustav
authors.initials: G
authors.lastname: Akk
mesh_terms: D000732:Androstanols / Q000737:chemistry / Q000494:pharmacology; D000818:Animals; D001665:Binding Sites; D002460:Cell Line; D058785:GABA-A Receptor Agonists; D006801:Humans; D006860:Hydrogen Bonding; D009154:Mutation; D018377:Neurotransmitter Agents / Q000737:chemistry / Q000378:metabolism*; D009570:Nitriles / Q000737:chemistry / Q000494:pharmacology; D009635:Norandrostanes / Q000737:chemistry / Q000494:pharmacology; D018408:Patch-Clamp Techniques; D051381:Rats; D011963:Receptors, GABA-A / Q000235:genetics / Q000378:metabolism*; D013329:Structure-Activity Relationship; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology
chemical_list: C495276:(3alpha,5beta,17beta)-3-hydroxy-18-norandrostane-17-carbonitrile; D000732:Androstanols; D058785:GABA-A Receptor Agonists; D018377:Neurotransmitter Agents; D009570:Nitriles; D009635:Norandrostanes; D011963:Receptors, GABA-A; C000658:androstan-3-ol; D005680:gamma-Aminobutyric Acid
references.citation: Proc Natl Acad Sci U S A. 1998 May 26;95(11):5998-6003
references.pmid: 9600906
references.citation: J Physiol. 2001 May 1;532(Pt 3):673-84
references.pmid: 11313438
references.citation: Neurotherapeutics. 2007 Jan;4(1):18-61
references.pmid: 17199015
references.citation: Mol Pharmacol. 2008 Sep;74(3):614-27
references.pmid: 18544665
references.citation: J Med Chem. 2003 Dec 4;46(25):5334-48
references.pmid: 14640542
references.citation: J Pharmacol Exp Ther. 1987 Apr;241(1):346-53
references.pmid: 3033209
references.citation: J Physiol. 2001 Dec 15;537(Pt 3):715-33
references.pmid: 11744750
references.citation: Pharm Res. 1996 Oct;13(10):1488-94
references.pmid: 8899839
references.citation: Br J Pharmacol. 2008 Feb;153(3):598-608
references.pmid: 18037909
references.citation: Mol Pharmacol. 2006 Jun;69(6):2015-26
references.pmid: 16554408
references.citation: J Med Chem. 2008 Mar 13;51(5):1309-18
references.pmid: 18275132
references.citation: Steroids. 2003 Nov;68(10-13):869-78
references.pmid: 14667979
references.citation: Biophys J. 1996 Jan;70(1):264-80
references.pmid: 8770203
references.citation: J Med Chem. 1996 Oct 11;39(21):4218-32
references.pmid: 8863799
references.citation: Nature. 1998 May 28;393(6683):392-6
references.pmid: 9620806
references.citation: J Neurosci. 2005 Dec 14;25(50):11605-13
references.pmid: 16354918
references.citation: Neuropharmacology. 2003 Jun;44(8):1003-12
references.pmid: 12763093
references.citation: J Physiol. 2002 Nov 1;544(3):695-705
references.pmid: 12411516
references.citation: Mol Pharmacol. 1996 Oct;50(4):931-8
references.pmid: 8863839
references.citation: Nature. 2006 Nov 23;444(7118):486-9
references.pmid: 17108970
references.citation: J Physiol. 2004 Jul 1;558(Pt 1):59-74
references.pmid: 15146041
references.citation: Pharmacol Ther. 2007 Oct;116(1):20-34
references.pmid: 17531325
references.citation: Mol Pharmacol. 2007 Jun;71(6):1582-90
references.pmid: 17341652